CLINICAL TRIALS PROFILE FOR BENZNIDAZOLE

505(b)(2) Clinical Trials for benznidazole

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT03981523 ↗	New Therapies and Biomarkers for Chagas Infection	Active, not recruiting	Barcelona Institute for Global Health	Phase 2	2019-12-18	Chagas disease (CD) is an endemic zoonotic disease with a significant global impact. Current approved treatments for CD (benznidazole (BZN) and nifurtimox (NFX)) were developed in the 1970s with regimens and dosing intervals derived from decades-old patient series and with very limited direct comparisons. Treatment recommendations vary significantly from country to country and the comparative evidence-base with the current treatment regimens is limited. The reported efficacy of both drugs in patients with T. cruzi infection is variable and depends on the disease stage, the drug dose, the age of patients, and the infecting T. cruzi strain or genotype. Due to a therapeutic failure of at least 20% after 12 months in chronic patients and the high rate of adverse events, together with the recent data that suggest that we may be overdosing patients, we propose to test new dosing regimens of these two old compounds. Hypotheses: - Lowering the frequency of drug dosing of BZN and NFX, the plasma drug levels of the drugs within the therapeutic range will be maintained. - The duration of treatment with BZN or NFX may be related to the effectiveness of these drugs. - Blood levels of the proposed biomarkers will significantly diminish or became negative after a relatively short interval after treatment.
New Dosage	NCT03981523 ↗	New Therapies and Biomarkers for Chagas Infection	Active, not recruiting	Drugs for Neglected Diseases	Phase 2	2019-12-18	Chagas disease (CD) is an endemic zoonotic disease with a significant global impact. Current approved treatments for CD (benznidazole (BZN) and nifurtimox (NFX)) were developed in the 1970s with regimens and dosing intervals derived from decades-old patient series and with very limited direct comparisons. Treatment recommendations vary significantly from country to country and the comparative evidence-base with the current treatment regimens is limited. The reported efficacy of both drugs in patients with T. cruzi infection is variable and depends on the disease stage, the drug dose, the age of patients, and the infecting T. cruzi strain or genotype. Due to a therapeutic failure of at least 20% after 12 months in chronic patients and the high rate of adverse events, together with the recent data that suggest that we may be overdosing patients, we propose to test new dosing regimens of these two old compounds. Hypotheses: - Lowering the frequency of drug dosing of BZN and NFX, the plasma drug levels of the drugs within the therapeutic range will be maintained. - The duration of treatment with BZN or NFX may be related to the effectiveness of these drugs. - Blood levels of the proposed biomarkers will significantly diminish or became negative after a relatively short interval after treatment.
New Dosage	NCT03981523 ↗	New Therapies and Biomarkers for Chagas Infection	Active, not recruiting	Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES)	Phase 2	2019-12-18	Chagas disease (CD) is an endemic zoonotic disease with a significant global impact. Current approved treatments for CD (benznidazole (BZN) and nifurtimox (NFX)) were developed in the 1970s with regimens and dosing intervals derived from decades-old patient series and with very limited direct comparisons. Treatment recommendations vary significantly from country to country and the comparative evidence-base with the current treatment regimens is limited. The reported efficacy of both drugs in patients with T. cruzi infection is variable and depends on the disease stage, the drug dose, the age of patients, and the infecting T. cruzi strain or genotype. Due to a therapeutic failure of at least 20% after 12 months in chronic patients and the high rate of adverse events, together with the recent data that suggest that we may be overdosing patients, we propose to test new dosing regimens of these two old compounds. Hypotheses: - Lowering the frequency of drug dosing of BZN and NFX, the plasma drug levels of the drugs within the therapeutic range will be maintained. - The duration of treatment with BZN or NFX may be related to the effectiveness of these drugs. - Blood levels of the proposed biomarkers will significantly diminish or became negative after a relatively short interval after treatment.

All Clinical Trials for benznidazole

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00123916 ↗	BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease	Completed	Canadian Institutes of Health Research (CIHR)	Phase 3	2004-11-01	Evaluate if benznidazole, an antiparasite drug, given at a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg) - reduces morbidity and mortality in patients with Chronic Chagas' Cardiomyopathy (CCC). The BENEFIT study is being conducted by the Population Health Research Institute (in Hamilton, Canada) and the Institute Dante Pazzanese de Cardiologia (Sao Paulo, Brazil) together with a Steering Committee, and an independent Safety Monitoring Board.
NCT00123916 ↗	BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease	Completed	Instituto Dante Pazzanese de Cardiologia	Phase 3	2004-11-01	Evaluate if benznidazole, an antiparasite drug, given at a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg) - reduces morbidity and mortality in patients with Chronic Chagas' Cardiomyopathy (CCC). The BENEFIT study is being conducted by the Population Health Research Institute (in Hamilton, Canada) and the Institute Dante Pazzanese de Cardiologia (Sao Paulo, Brazil) together with a Steering Committee, and an independent Safety Monitoring Board.
NCT00123916 ↗	BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease	Completed	University of Sao Paulo	Phase 3	2004-11-01	Evaluate if benznidazole, an antiparasite drug, given at a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg) - reduces morbidity and mortality in patients with Chronic Chagas' Cardiomyopathy (CCC). The BENEFIT study is being conducted by the Population Health Research Institute (in Hamilton, Canada) and the Institute Dante Pazzanese de Cardiologia (Sao Paulo, Brazil) together with a Steering Committee, and an independent Safety Monitoring Board.

Clinical Trial Conditions for benznidazole

Condition Name

Condition Name for benznidazole
Intervention	Trials
Chagas Disease	18
Trypanosoma Cruzi Infection	2
Chronic Chagas Disease	2

Condition MeSH

Condition MeSH for benznidazole
Intervention	Trials
Chagas Disease	22
Trypanosomiasis	3
Inflammation	1

Clinical Trial Locations for benznidazole

Trials by Country

Trials by Country for benznidazole
Location	Trials
Argentina	22
Brazil	18
Bolivia	10
Colombia	8
Spain	5

Trials by US State

Trials by US State for benznidazole
Location	Trials
Texas	1
Massachusetts	1
Louisiana	1
California	1

Clinical Trial Progress for benznidazole

Clinical Trial Phase

Clinical Trial Phase for benznidazole
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	1
Phase 4	3

Clinical Trial Status

Clinical Trial Status for benznidazole
Clinical Trial Phase	Trials
Completed	11
Unknown status	5
Recruiting	5

Clinical Trial Sponsors for benznidazole

Sponsor Name

Sponsor Name for benznidazole
Sponsor	Trials
Drugs for Neglected Diseases	8
Hospital Universitari Vall d'Hebron Research Institute	2
Barcelona Centre for International Health Research	2

Sponsor Type

Sponsor Type for benznidazole
Sponsor	Trials
Other	52
Industry	7
NIH	1

Last updated: July 22, 2026

Benznidazole clinical trials update, market analysis, and global sales projection (2025–2035)

Benznidazole is an established antiparasitic drug used primarily for Chagas disease (Trypanosoma cruzi) and for second-line/selected indications where it is locally approved. Market growth is constrained by long-standing generic availability in many jurisdictions, uneven access, and limited late-stage pipeline activity in the public domain. The commercial outlook through 2035 depends more on programmatic procurement for Chagas control than on new commercial launches.

What is the current clinical trial landscape for benznidazole?

Answer: Public registries show intermittent interventional studies rather than a continuous late-stage Phase 3 program. Trial activity clusters around (1) optimized treatment regimens (dose, duration, adherence support), (2) pediatric studies, (3) comparative effectiveness across care pathways, and (4) safety/tolerability refinements. Studies that assess parasitological endpoints and long-term outcomes (seroconversion/clearance, cardiac outcomes) are typically slow, which reduces near-term pipeline monetization.

Which trial types are most common in recent benznidazole studies?

• Dose and duration optimization: shorter vs standard duration, or regimen modifications tied to tolerability.
• Pediatric and adolescent pharmacology: dosing strategy, safety monitoring, and weight-based adjustments.
• Adherence and management of adverse events: interventions to reduce discontinuation from rash, neuropathy, or hematologic toxicity.
• Comparative “care pathway” designs: integration with follow-up schedules, diagnostics, and cardiac monitoring.

Are there any active Phase 3 trials that could change the market?

Answer: No clear, widely documented Phase 3 program is likely to drive a major market re-shaping event for benznidazole specifically in the short-to-mid term. The drug’s role is entrenched, and new competitive advantage usually requires either (a) a differentiated formulation, (b) an improved safety profile with regulatory labeling expansion, or (c) a new combination strategy with clear superior outcomes.

What endpoints drive benznidazole trial execution?

• Parasitological measures are used early, but many studies rely on serologic response over time.
• Cardiac and neurologic outcomes are relevant for long-run clinical value in chronic Chagas.
• Safety endpoints focus on dermatologic reactions, peripheral neuropathy, and hematologic changes that drive dose interruption or discontinuation.

How is the benznidazole market segmented by geography and indication?

Answer: Demand is concentrated in endemic Latin America for Chagas control and in global health procurement and screening programs. Outside endemic regions, volumes depend on immigrant health screening and tertiary referral in Europe and North America.

Endemic region demand drivers

• Public health programs tied to Chagas screening and treatment referrals.
• Inclusion in national guidelines and procurement tender structures.
• Availability of diagnostic programs that identify chronic and early infection cases eligible for benznidazole.

Non-endemic region demand drivers

• Health system pathways for diagnosed Chagas in immigrant populations.
• Hospital or specialty clinic treatment for chronic Chagas where alternatives are not preferred or where benznidazole is selected by clinician preference.

Substitution and competitive intensity

• Nifurtimox is the closest comparator used in some jurisdictions, but it is not a uniform substitute.
• Generic benznidazole exists widely; market share is typically won through procurement contracts, distribution coverage, and supply reliability rather than patent exclusivity.

What is the Orange Book status of benznidazole in the US?

Answer: Benznidazole is not marketed in the US under an Orange Book–typical branded FDA approval with associated listed patents in the way many commercial small-molecule drugs are. Clinical use in the US historically has relied on nonstandard distribution pathways (including government access programs), and importation or supply through authorized channels has been common in practice.

Why Orange Book status matters for exclusivity

If Orange Book patent listings are absent or limited, the US market tends to operate as a generic-access market with reduced leverage from new patent filings, and any exclusivity advantage usually comes from regulatory exclusivity for specific labeling updates or from supply contracts rather than from classic paragraph IV leverage.

When does benznidazole lose exclusivity, and what does that mean for generic entry?

Answer: For benznidazole, generic availability is already established in many markets, so exclusivity-driven generic timing is typically not the binding constraint. In most geographies, the limiting factor is manufacturing capacity, procurement tender timing, and quality system readiness rather than IP barriers.

What are the generic entry risks in practice?

• CMC and bioequivalence/quality: ensuring consistent API sourcing and dissolution/profile equivalence where required.
• Supply chain: raw material availability, lead times, and compliance audits.
• Regulatory acceptance: local registration and labeling alignment with guidelines.
• Contracting: national procurement often requires demonstrated supply continuity.

What patents protect benznidazole formulations, and are there meaningful barriers to copycat products?

Answer: For benznidazole itself, core compound protection is long expired in most jurisdictions. The practical IP landscape for new entrants is usually framed around formulations, manufacturing processes, and product-specific regulatory dossiers rather than novel active substance claims.

Formulation and manufacturing IP focus areas

• Solid dosage characteristics: particle size control, polymorph management, and stability.
• Stabilizers/excipients: where local regulators or quality programs drive differences.
• Process patents: crystallization, drying conditions, and impurity control.
• Combination products: fixed-dose combinations with a second antiparasitic can introduce new protection and regulatory pathways, but these are less common for benznidazole specifically.

How does benznidazole compare with nifurtimox for clinical and market positioning?

Answer: Clinically, both are used for Chagas disease, but tolerability profiles differ and drive treatment selection in practice. Nifurtimox can be limited by adverse events in some settings, and benznidazole is often the preferred option in many guideline-based workflows where tolerated.

Market implication

If both drugs are generic, the competitive outcome is driven by:

• national procurement preferences,
• adverse event management protocols,
• patient adherence patterns,
• and availability of diagnostics that allow appropriate patient selection.

What are the biggest adverse event considerations shaping trial design and payer demand?

Answer: Benznidazole is associated with treatment-limiting toxicities that shape dosing interruption rates and adherence.

Safety profile topics commonly monitored

• Peripheral neuropathy (dose limiting)
• Dermatologic reactions (rash)
• Hematologic toxicity (less frequent but important in monitoring plans)
• GI intolerance impacting adherence

How does safety affect market demand?

• Programs need monitoring capacity to maintain treatment completion.
• Payers and procurement programs favor predictable dosing schedules and clear adverse event management guidance.

What FDA regulatory pathway governs benznidazole access and labeling in major markets?

Answer: Regulatory status depends on jurisdiction. In the US, benznidazole access has historically been mediated through authorized distribution rather than through a standard commercial branded pathway with broad patent-protected exclusivity. In Latin America and other high-burden regions, local registrations and generic approvals are more central to market access.

Labeling and guideline alignment

Market uptake tracks local alignment with treatment guidelines and diagnostic screening programs that identify eligible patients for benznidazole therapy.

Which companies are most active in benznidazole manufacturing and distribution?

Answer: The market is largely served by generic manufacturers and authorized distributors in endemic regions and through import channels into non-endemic countries. In many public discussions of Chagas treatment supply, multiple generics appear as procurement options, but direct brand-level market share data is rarely published with high granularity.

Commercial reality

• Procurement contracts drive volumes.
• Supply reliability and quality system performance are decisive.
• Distribution coverage in public tender geographies often matters more than brand promotion.

Clinical trial investment: is there a combination or next-generation opportunity for benznidazole?

Answer: The most plausible commercial “next step” for benznidazole is not a stand-alone new label for the active ingredient, but combination strategies or regimen optimization that improve completion rates and long-term outcomes.

Where the risk/reward tends to sit

• Safety-driven trial costs are high due to long follow-up requirements for chronic outcomes.
• Any combination that meaningfully improves response could create differentiation even in a generic-active compound market.

Global market analysis for benznidazole (2025–2035): demand, pricing, and volumes

Answer: Benznidazole demand is tied to Chagas burden, screening program scale, and treatment eligibility rates, not to patent-led innovation. Pricing is constrained by generic competition, so value growth is limited; volume growth depends on program coverage and diagnostic expansion.

Market model drivers

1. Chagas prevalence and annual incidence screening
2. Eligibility rate for benznidazole treatment (timing of diagnosis: early vs chronic)
3. Treatment adherence/completion rates (safety management capacity)
4. Procurement continuity (supply constraints can cap treated patients)
5. Local generic price trends driven by competition and tender cycles

Indicative projection framework (how 2035 sales would be reached)

• Base volume: number of patients treated annually under guideline-consistent programs.
• Average selling price (ASP): subject to tender competition and generic pricing erosion.
• Scenario sensitivity:
  • If screening expands faster than treatment capacity, volume growth accelerates.
  • If safety management gaps increase discontinuation, effective treated course completion lags.

Sales projection table: benzidazole global market outlook (scenario-based, 2025–2035)

The following is a scenario structure used for forecasting in generic-constrained, program-driven markets like benznidazole. It is organized to be used in underwriting and commercial planning: volume growth is modeled from program scaling; pricing erosion is modeled from generic competition intensity.

Year	Low-growth scenario (Index)	Base scenario (Index)	High-growth scenario (Index)	What changes
2025	100	100	100	baseline procurement mix
2027	104	108	113	incremental screening expansion
2030	110	120	135	tender expansion and improved access
2033	117	133	155	better diagnostics and higher eligible treatment rates
2035	123	145	175	sustained program coverage, limited supply disruptions

How to interpret:

• “Index” reflects directional sales movement, not absolute currency, because public high-quality, drug-specific revenue datasets for benznidazole are typically fragmented by geography and formulation.
• The model emphasizes that global growth is mostly volume-led with limited price-led upside.

What settlement or litigation risks exist for benznidazole?

Answer: Classic US paragraph IV litigation is not a dominant feature for benznidazole because the market is not typically driven by an Orange Book branded exclusivity framework. Legal risk more often appears in:

• patent disputes related to formulation/process improvements, and
• regulatory or quality enforcement disputes (GMP, data integrity, labeling compliance).

What patent estate strength is relevant for benznidazole going forward?

Answer: The core active ingredient estate is not the binding constraint. The relevant estate (where present) is usually:

• incremental formulation and process protection,
• improvements tied to manufacturing impurities,
• or combination/regimen IP tied to clinical protocols.

Which clinical trial updates would matter commercially for benznidazole?

Answer: Only changes that affect either (a) treatment duration, (b) safety-adverse event management leading to higher completion rates, or (c) improved long-term response in chronic Chagas would be likely to shift procurement and reimbursement behaviors.

“Commercially meaningful” trial signals

• Higher completion rates without increased serious adverse events.
• Improved long-term parasitological or clinical outcome measures.
• Pediatric safety and efficacy signals that expand eligible cohorts.
• Evidence that a modified monitoring or dose adjustment protocol prevents neuropathy/rash leading to discontinuation.

Key Takeaways

• Benznidazole demand tracks Chagas screening and treatment program scale; innovation-driven exclusivity is not the main market driver.
• Public clinical trial activity is episodic and mostly focuses on regimen optimization and safety/adherence management rather than a disruptive Phase 3 new-efficacy breakthrough.
• Generic availability constrains pricing power in most markets; procurement contracting and supply reliability dominate commercial outcomes.
• Global sales growth through 2035 is most plausibly volume-led, with the largest upside tied to expanded diagnostics and improved access in endemic regions.

FAQs

1. What dosing regimen is commonly used for benznidazole in chronic Chagas in clinical practice?
2. Do pediatric benznidazole studies show different safety outcomes than adult populations?
3. How do diagnostic timing and staging (acute vs chronic Chagas) affect benznidazole eligibility and trial endpoints?
4. What manufacturing impurities and CMC controls are most relevant for generic benznidazole approvals?
5. Is benznidazole used as part of combination therapy in any guideline-based protocols, and how does that affect market sizing?

References

1. World Health Organization (WHO). Chagas disease. https://www.who.int/
2. ClinicalTrials.gov. Benznidazole studies (trial listings). https://clinicaltrials.gov/
3. FDA. Drug development and regulatory information (general reference). https://www.fda.gov/
4. Drugs@FDA. Benznidazole-related records (general database access). https://www.accessdata.fda.gov/scripts/cder/daf/